BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24277452)

  • 1. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.
    Zeng ZL; Luo HY; Yang J; Wu WJ; Chen DL; Huang P; Xu RH
    Clin Cancer Res; 2014 Feb; 20(4):1042-52. PubMed ID: 24277452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway.
    Jiang W; Zhao S; Jiang X; Zhang E; Hu G; Hu B; Zheng P; Xiao J; Lu Z; Lu Y; Ni J; Chen C; Wang X; Yang L; Wan R
    Cancer Lett; 2016 Feb; 371(2):314-25. PubMed ID: 26683776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma.
    Tang Q; Cheng B; Xie M; Chen Y; Zhao J; Zhou X; Chen L
    Cancer Res; 2017 Jan; 77(2):532-544. PubMed ID: 27821487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
    Cristóbal I; Rincón R; Manso R; Caramés C; Zazo S; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Clin Cancer Res; 2015 Jan; 21(2):347-56. PubMed ID: 25388166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity.
    Zeng ZL; Wu MW; Sun J; Sun YL; Cai YC; Huang YJ; Xian LJ
    J Biochem; 2010 Sep; 148(3):319-26. PubMed ID: 20576619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer.
    Kong Y; Bai PS; Sun H; Nan KJ; Chen NZ; Qi XG
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2321-32. PubMed ID: 22903020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
    Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
    Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis.
    Zhang N; Li X; Wu CW; Dong Y; Cai M; Mok MT; Wang H; Chen J; Ng SS; Chen M; Sung JJ; Yu J
    Oncogene; 2013 Oct; 32(42):5078-88. PubMed ID: 23208495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.
    Burgermeister E; Battaglin F; Eladly F; Wu W; Herweck F; Schulte N; Betge J; Härtel N; Kather JN; Weis CA; Gaiser T; Marx A; Weiss C; Hofheinz R; Miller IS; Loupakis F; Lenz HJ; Byrne AT; Ebert MP
    EBioMedicine; 2019 Jul; 45():139-154. PubMed ID: 31300350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
    Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
    Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Circadian Clock Regulates Metabolic Phenotype Rewiring Via HKDC1 and Modulates Tumor Progression and Drug Response in Colorectal Cancer.
    Fuhr L; El-Athman R; Scrima R; Cela O; Carbone A; Knoop H; Li Y; Hoffmann K; Laukkanen MO; Corcione F; Steuer R; Meyer TF; Mazzoccoli G; Capitanio N; Relógio A
    EBioMedicine; 2018 Jul; 33():105-121. PubMed ID: 30005951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    Chian S; Li YY; Wang XJ; Tang XW
    Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies.
    Taniguchi H; Fernández AF; Setién F; Ropero S; Ballestar E; Villanueva A; Yamamoto H; Imai K; Shinomura Y; Esteller M
    Cancer Res; 2009 Nov; 69(21):8447-54. PubMed ID: 19861541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
    Lu WQ; Hu YY; Lin XP; Fan W
    Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-expression of circadian clock gene Bmal1 affects proliferation and the canonical Wnt pathway in NIH-3T3 cells.
    Lin F; Chen Y; Li X; Zhao Q; Tan Z
    Cell Biochem Funct; 2013 Mar; 31(2):166-72. PubMed ID: 22961668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
    Yang C; Liu HZ; Lu WD; Fu ZX
    Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian clock gene
    Zhao C; Meng X; Li Y; Liu L; He Q; Jiang J; Chen Y; Li X; Li Y; Tang Y; Zhou D; Zhou J; Jin F
    Chronobiol Int; 2022 Oct; 39(10):1340-1351. PubMed ID: 35903031
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.